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Accounting for justifiable variance is important for fair comparisons of treatment quality.
The variance between general practices in treatment quality of type 2 diabetes (T2DM)
patients may be attributed to the underlying patient population and practice characteristics.
The objective of this study is to describe the between practice differences in treatment, and
identify patient and practice level characteristics that may explain these differences.
Methods
The data of 24,607 T2DM patients from 183 general practices in the Netherlands were
used. Treatment variance was assessed in a cross-sectional manner for: glucose-lowering
drugs/metformin, lipid-lowering drugs/statins, blood pressure-lowering drugs/ACE-inhibitor
or ARB. Patient characteristics tested were age, gender, diabetes duration, comorbidity,
comedication. Practice characteristics were number of T2DM patients, practice type, diabe-
tes assistant available. Multilevel logistic regression was used to examine the between
practice variance in treatment and the effect of characteristics on this variance.
Results
Treatment rates varied considerably between practices (IQR 9.5–13.9). The variance at
practice level was 7.5% for glucose-lowering drugs, 3.6% for metformin, 3.1% for lipid-low-
ering drugs, 10.3% for statins, 8.6% for blood pressure-lowering drugs, and 3.9% for ACE-
inhibitor/ARB. Patient and practice characteristics explained 19.0%, 7.5%, 20%, 6%, 9.9%,
and 13.4% of the variance respectively. Age, multiple chronic drugs, and3 glucose-lower-
ing drugs were the most relevant patient characteristics. Number of T2DM patients per
practice was the most relevant practice characteristic.
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Discussion
Considerable differences exist between practices in treatment rates. Patients’ age was
identified as characteristic that may account for justifiable differences in especially lipid-low-
ering treatment. Other patient or practice characteristics either do not explain or do not jus-
tify the differences.
Background
Quality assessment frameworks have been introduced in several countries with the goal to
ensure appropriate and evidence-basedhealthcare for patients [1]. Within such frameworks,
guideline recommendations on optimal care are linked to performancemeasures and account-
ability processes. Performance measures assess to what extent care is delivered according to
guideline recommendations.When applying such measures in clinical practice, variation in the
performance of healthcare providers and institutions is common. For example, prescribing of
preferred drugs by Dutch general practitioners ranged from 35% to 95%, whereas prescribing
drug treatment when indicated ranged from 60% to 95% [1]. Differences in performancemay
be attributed to the underlying patient population as well as to the healthcare provider and the
practice organization.
In heterogeneous populations, it is to be expected that healthcare provider’s treatment deci-
sions are influenced by differences in patient characteristics. For example, patients with type 2
diabetes (T2DM) commonly have multiple conditions and risk factors which may require indi-
vidualized treatment plans. A recent review concluded that patient characteristics, such as mar-
ital status and BMI, affect outcome measures for diabetes but no consistent patterns were
observed for process measures [2]. Previous research indicates that patient characteristics, such
as age [3, 4], gender [5, 6], disease duration [7], comorbidity presence [8], and level of risk fac-
tor control [9, 10], can all influence prescribing in this population. This may reflect appropriate
care, for example, when different treatment regimens are considered for elderly patients [11,
12], or intensified treatment is prescribed for patients with more progressed disease states [13].
Variance may also be justifiable when there are competing demands [14, 15] or when patients
are reluctant or unwilling to take specific or more drugs [16]. In other cases, variance can be
non-justifiable, for example, when prescription rates for guideline recommended treatment dif-
fer in men and women [5, 6]. Healthcare providers’ personal preferences, knowledge and habits
can influence treatment decisions. For example, physicians may differ in their preferences for
certain types of treatment, or in their reluctance or keenness to prescribe [10, 17, 18]. In addi-
tion, practice characteristics, such as practice type, size, consultation time, and the presence of
support staff have been found to influence prescribing behavior [19, 20]. These factors may
contribute to non-justifiable variance between practices. Accounting for patient characteristics
causing justifiable differences is important for fair between practice comparisons of treatment
quality. The aim of this study is to describe the differences in treatment quality of patients with
diabetes between general practices, and identify patient and practice level characteristics that
may explain these differences.
Methods
Study design and setting
We conducted a cross-sectional study to assess treatment quality in 2012 in a large diabetes
care group in The Netherlands, which includedmore than 80% of all general practices in the
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province of Groningen. Diabetes care groups have been formed after the introduction of bun-
dled payment in 2007 [21]. They are responsible for the organization and provision of diabetes
care in accordance with the Dutch clinical practice guidelines.
Study population and data collection
Data were collected from the GIANTT (Groningen Initiative to Analyze Type 2 Diabetes) data-
base. This regional longitudinal database contains anonymized data extracted from electronic
medical records of almost all type 2 diabetes mellitus (T2DM) patients (<1% opted out) man-
aged in general practice [22]. The database includes prescription data, medical history, results
from routine laboratory tests and physical examinations. Medical history consists of diagnoses,
which are documented in the medical records by means of the International Classification of
Primary Care (ICPC) or short text descriptions which are manually coded. From the 189 gen-
eral practices in GIANTT, 6 were excluded for having incomplete prescription or diagnostic
data. Patients diagnosedwith T2DM before 1 January 2012 were selected. Patients with incom-
plete follow-up in 2012, and patients with missing or invalid onset dates for diabetes were
excluded.
Outcomes: treatment measures
Treatment quality was defined as current treatment status, that is, if a patient was treated or
not with guideline recommended drug treatment, similar to many of the prescribing measures
currently in use in The Netherlands [23]. We focused on whether any drug treatment was pre-
scribed for eligible patients, and whether the first-choice drug class was prescribed for three
common risk factors. This includes treatment in T2DM patients with (1) any glucose-lowering
drug, (2) any lipid-lowering drug in patients with an additional diagnosis of dyslipidemia, vas-
cular comorbidity or nephropathy, and (3) any blood pressure-lowering drugs in patients with
an additional diagnosis of hypertension, vascular comorbidity or nephropathy. In the Nether-
lands, general practitioners may prescribe any drug to treat a specific risk factor or indication
that is allowed on the Dutch market, but some drugsmay have restrictions for reimbursement.
Any glucose-lowering treatment included: metformin, sulfonylureas, acarbose, thiazolidine-
diones, dipeptidyl-peptidase-4-inhibitors, insulins, and other blood glucose–loweringdrugs
(e.g. exenatide, dapagliflozin). Any lipid-lowering treatment included: statins, fibrates, bile acid
sequestrants, nicotinic acid and derivatives, and other lipid-modifying drugs (e.g. ezitimibe).
Any blood pressure-lowering treatment included: centrally acting antihypertensives, diuretics,
β-blockers, calcium channel blockers, and drugs acting on the renin–angiotensin system.
Within the above defined patients the first choice drug classes recommended by Dutch guide-
line for diabetes care [24] comprised of treatment with (1) metformin, (2) statins, and (3)
drugs acting on renin-angiotensin-aldosterone system (RAAS-blockers). A patient was consid-
ered as being treated when a prescription was recorded within the last 4 months of 2012, taking
into account that a prescription can be issued for a maximum period of 3 months in the
Netherlands.
Explanatory variables
To explain the differences in treatment between practices, the following patient level character-
istics were included as dichotomous variables: age (70 years for glucose lowering treatment,
80 years for blood pressure and lipid lowering treatment), gender, duration of diabetes (2
years), overweight (ICPC-1 codes: T82, T83), history of cardiovascular comorbidity (ICPC-1
codes: K74-K77, K84, K99.1, left ventricular hypertrophy, coronary artery bypass graft, percu-
taneous transluminal coronary angioplasty), history of peripheral vascular comorbidity (ICPC-
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1 codes: K89-K92, peripheral bypass, percutaneous transluminal angioplasty), diabetes compli-
cations (ICPC-1 codes: K99.6, F83, N94.2), nephropathy (ICPC-1 codes: U90, U99.1, U99.2,
U99.3, dialysis, or kidney transplantation), history of malignancy (ICPC-1 codes: A79,
B72-B74, D74-D77, F74.1, H75.1, K72.1, L71.1, N74, R84, R85, S77, T71, U75-U77, X75-X77,
Y77, Y78), history of psychological disorders (ICPC-1 codes: P70-P80, P85, P98, P99), treat-
ment with 5 or more other chronic drug classes (ATC codes starting with A, B, C, H, L, M, N,
R, excluding antihypertensive, glucose-regulating, and lipid-regulating drugs), treatment with
3 or more glucose lowering drug classes, treatment with 4 or more blood pressure lowering
drug classes, and treatment with 2 or more lipid lowering drug classes. The cutoff levels for age
were based on the Dutch guideline [24] where less stringent treatment targets are recom-
mended for elderly patients. The cutoff level for diabetes duration was chosen to distinguish
patients who were recently diagnosedwith T2DM (diabetes duration< 2 years) from those
having diabetes for a longer period ( 2 years). The cutoff levels for the number of chronic
medications and numbers of glucose, blood pressure, and lipid lowering medication were cho-
sen to indicate the burden of being on high numbers of drug classes unrelated to the outcome
of interest (e.g. the variable determining treatment with 3 or more glucose lowering drug clas-
ses was not used in the models where outcome was defined as treatment with glucose-lowering
drugs or metformin). The following general practice level characteristics were included in
order to explain potentially non-justifiable differences in treatment between practices: number
of diabetes patients per practice, presence of educated diabetes assistant, and practice type
(solo or group).
Statistical analysis
The treatment quality rates were described at practice level as mean percentages with standard
deviation, or median percentages with interquartile ranges. Descriptive statistics were also used
to describe the distribution of patient characteristics across general practices.
Multilevel logistic regression analysis was conducted for each of the six treatment measures
separately (using Stata 14.1, Special Edition) to assess the variance that is attributed to general
practice level and the part of this variance that can be explained by patient and practice charac-
teristics. Two level random intercept models were estimated with patients at level 1 nested
within general practices at level 2. In these models the probability for the treatment outcome
can vary across practices but the effect of the patient characteristics is assumed to be the same
(fixed) for all practices.
First, the variance in treatment at practice level was estimated in an empty multilevel model.
Second,multilevel univariate analyses were conducted for each patient and practice level
explanatory variable. Next, three multivariate models were built using backwards selection for
including variables that were potentially associated with the treatment measure (p<0.2); (i)
model 1, with patient level characteristics only, (ii) model 2, with general practice characteris-
tics only, (iii) model 3, with patient and practice characteristics together.
The pseudo R2 measure was used to estimate what part of the variance at practice level
could be explained by including patient and general practice characteristics [25, 26]. For this,
the percentages reduction in pseudo R2 were calculated for each model compared to the empty
model, expressing the part of the practice level variance that can be explained by the included
characteristics.
Ethics statement
In The Netherlands, according to the Code of Conduct for the use of data in Health Research
(‘Gedragscode gezondheidsonderzoek’ approved in 2004 by the Dutch College for Protection
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of Personal Data, taking into account Article 25 of the Dutch Act on the Protection of Personal
Data), no ethics committee approval was needed for this research using data from anonymous
medical records.
Result
A cohort of 24,628 patients with T2DMmanaged in 183 general practices was eligible, after
excluding 974 patients for incomplete follow-up and 27 patients for missing or invalid diabetes
onset dates. Of the 183 general practices, 90.7% had a diabetes assistant and 45.4% were prac-
tices with a single general practitioner (Table 1). The median number of T2DM patients per
practice was 122 with a range from 15 to 480 patients. The proportion of patients with comor-
bidity, hypertension, dyslipidemia and overweight, varied widely across the practices. Among
the eligible patients, 75.3% of patients were treated with glucose-lowering drugs, 73.7% with
lipid-lowering drugs, and 87.8% with blood pressure-lowering drugs. Considerable differences
(IQR 9.5–13.9) were observed in these treatment rates between general practices (Table 2). The
between practice variance in the empty multilevel model was 7.5% for glucose-lowering treat-
ment, 3.6% for metformin, 3.1% for lipid-lowering treatment, 10.3% for statins, 8.6% for blood
pressure-lowering treatment, and 3.9% for RAAS-blockers (Table 3). The models including all
the characteristics (model 3) are presented in Table 4 reflecting the effect sizes of the associa-
tions between the included characteristics and treatment outcomes.
For glucose lowering drugs, patient and practice characteristics together reduced the prac-
tice level variance with 1.4%, and thereby explained 19.0% of the observedpractice level










Diabetes patients per practice 122.0 (77.0) 15–480
Solo practice (%) 83 45.4
Practice assistant (%) 166 90.7
Patient level 24,628
Gender, female (%) 12,571 51 50.8 (6.3) 20–65.8
Age (years) 24,628 67.0 (17.0) 67.1 (2.7) 59.5–74.0
Diabetes duration (years) 24,628 5.0 (7.0) 6.2 (1.3) 3.8–9.5
History of cardiovascular
comorbidity (%)
5,320 21.6 22.2 (14.9) 0.0–46.5
History of peripheral vascular (%) 2,888 11.7 11.1 (8.9) 0.0–56.0
Diabetes complications (%) 2,380 9.7 8.2 (11.4) 0–30.1
History of malignancy (%) 3,281 13.3 13.7 (11.3) 0.0–53.3
History of psychological disorders
(%)
2,500 10.2 8.6 (8.3) 0.0–36.9
Hypertension (%) 12,345 50.1 51.2 (31.7) 1.6–88.2
Dyslipidemia (%) 4,747 19.3 14.6 (19.0) 0.0–79.5
Nephropathy (%) 1,275 5.2 3.3 (6.0) 0.0–30.1
Overweight (%) 11,526 46.8 50.0 (26.6) 3.5–83.1
5 chronic drugs (%) 6,916 28.1 26.9 (9.7) 12.4–45.7
3 glucose lowering drugs (%) 2,568 10.4 10.5 (6.1) 0.0–20.9
2 lipid lowering drugs (%) 753 3.1 2.8 (2.5) 0.0–12.8
4 blood pressure lowering drugs
(%)
2,939 11.9 11.8 (5.3) 0.0–32.1
doi:10.1371/journal.pone.0166012.t001
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variance in treatment (Table 3). Each of the tested patient characteristics explained less than
2% of the variance in the univariate analyses (S1 Appendix). Together, patient characteristics
explained only 3.3% of the variance. Practice characteristics, in turn, explained 15.5% of the
variance. For metformin, adjusting for patient characteristics reduced the practice level vari-
ance with 0.3% thereby explaining 7.5% of the variance in treatment. In the univariate analyses
age of patient and use of5 chronic drugs were the characteristics that explained the most of
the practice level variance. Practice characteristics did not explain any practice level variance in
treatment with metformin.
For lipid-lowering drugs and statins, patient and practice characteristics together reduced
the practice level variance with 0.6% each, and thereby explained 20% and 6% of this variance
respectively (Table 3). Age, treatment with 3 or more glucose-lowering drugs, and number of
patients with T2DM per practice explained between 2.9% and 5.8% of the variance in treatment
with lipid-lowering drugs in the univariate analyses (S1 Appendix). Together, patient
Table 2. Proportion of patients treated and the between practice differences in treatment rate.








Glucose-lowering drugs 24628 18547 75.3 77.9 (13.9) 39.1–95.7
Metformin 18547 15572 83.9 84.7 (7.5) 60.2–100
Lipid-lowering drugs 10272 7567 73.7 74.3 (13.2) 43.8–100
Statins 7567 7375 97.5 98.6 (3.7) 66.7–100
Blood pressure-lowering
drugs
15369 13487 87.8 90.4 (9.5) 55.6–100
RAAS-blockers* 13487 10590 78.5 80.4 (10.2) 45.3–100
* RAAS-blockers: renin-angiotensin-aldosterone system blockers
doi:10.1371/journal.pone.0166012.t002
Table 3. Proportion and reduction of variance in treatment attributed to practice level.
Variance at practice level (%)*
Glucose-lowering drugs Metformin
proportion reduction proportion reduction
Empty model: crude practice level variance 7.5 3.6
Model 1: including patient characteristics only 7.3 0.2 3.3 0.3
Model 2: including practice characteristics only 6.4 1.1 3.6 0
Model 3: including patient and practice characteristics** 6.1 1.4 3.3 0.3
Lipid-lowering drugs Statins
proportion reduction proportion reduction
Empty model: crude practice level variance 3.1 10.3
Model 1: including patient characteristics only 2.8 0.3 10.2 0.1
Model 2: including practice characteristics only 2.9 0.2 9.6 0.7
Model 3: including patient and practice characteristics** 2.5 0.6 9.6 0.7
Blood pressure-lowering drugs RAAS-blockers
proportion reduction proportion reduction
Empty model: crude practice level variance 8.5 3.9
Model 1: including patient characteristics only 6.7 1.8 3.8 0.1
Model 2: including practice characteristics only 8.2 0.3 3.7 0.2
Model 3: including patient and practice characteristics** 6.4 2.1 3.4 0.5
* Pseudo R2 for the two level fixed effect random intercept models
** Model 3 included the variables with the effect size from Table 4
doi:10.1371/journal.pone.0166012.t003
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characteristics explained 9.9% of the variance in treatment with lipid-lowering drugs and 0.3%
of the variance in treatment with statins. Practice characteristics explained 8.3% and 6.0% of
the variance respectively.
For blood pressure-lowering drugs and RAAS-blockers, patient and practice characteristics
together reduced the practice level variance with 2.1% and 0.5% respectively, and thereby
explained 9.9% and 13.4% of this variance (Table 3). A history of psychological comorbidity
and number of T2DM patients per practice explained 3.7% and 4.3% of the variance in treat-
ment with blood pressure-lowering drugs in the univariate analysis (S1 Appendix). Together,
patient characteristics explained 6.2% of the variance in treatment with blood pressure-lower-
ing drugs and 7.2% of the variance in treatment with RAAS-blockers. Practice characteristics
explained 4.3% and 5.9% of the variance.
Discussion
We observed considerable between practice differences in treatment with glucose-lowering,
lipid-lowering, blood pressure-lowering drugs, and RAAS-blockers (IQR ranges of 10% or
more) in T2DM patients. Smaller between practice differences in treatment were observed in
Table 4. Effect sizes of the association between the characteristics and treatment outcomes as described in model 3 in the methods (all the
selected variables are included into the models).
Model Treatment with
glucose-lowering
















Age 0.76 (0.71–0.81) 0.55 (0.50–0.60) 0.37 (0.33–0.41) NA 0.68 (0.60–0.77) 0.77 (0.69–0.86)
Female gender 0.81 (0.76–0.86) 0.75 (0.69–0.82) 0.73 (0.67–0.80) 0.83 (0.62–1.11) 1.08 (0.98–1.19) 0.80 (0.73–0.87)
Diabetes duration 3.16 (2.97–3.38) 0.57 (0.51–0.63) 1.08 (0.97–1.20) NA NA 1.37 (1.25–1.51)
Hypertension 0.92 (0.86–0.99) 1.15 (1.05–1.25) NA NA NA NA
Dyslipidemia NA NA NA NA NA NA
Nephropathy 0.83 (0.72–0.96) NA NA NA NA NA
Overweight 1.35 (1.27–1.45) 1.09 (0.99–1.18) NA NA 1.34 (1.21–1.49) 1.23 (1.12–1.34)
Cardiovascular
comorbidity
NA 0.87 (0.79–0.96) NA NA NA NA
Peripheral vascular
comorbidity
NA 0.84 (0.74–0.95) NA NA NA NA
Diabetes
complications
1.14 (1.02–1.27) 0.87 (0.76–0.99) 0.83 (0.73–0.95) NA 0.86 (0.74–1.00) NA
Malignancy 0.87 (0.80–0.95) 0.87 (0.78–0.98) 0.81 (0.72–0.91) 0.77 (0.54–1.11) NA NA
Psychological
disorder
0.81 (0.74–0.90) NA 0.77 (0.67–0.88) NA 0.61 (0.53–0.70) 0.81 (0.71–0.92)
5 chronic drugs NA 0.61 (0.55–0.66) NA 0.82 (0.60–1.10) 1.29 (1.15–1.44) 0.73 (0.67–0.80)
3 glucose-lowering
drugs
NA NA 1.39 (1.18–1.64) NA 1.41 (1.17–1.70) 1.11 (0.97–1.29)
2 lipid-lowering
drugs
1.53 (1.25–1.89) 1.31 (1.02–1.68) NA NA NA 1.28 (0.98–1.63)
4 blood pressure-
lowering drugs
1.36 (1.23–1.51) NA 1.42 (1.25–1.61) NA NA NA
Solo practice NA NA 0.86 (0.75–0.99) NA NA NA
Assistant presence 0.72 (0.54–0.95) NA NA 1.54 (0.87–2.71) NA NA
Number of T2DM
patients per practice
0.99 (0.99–0.99) NA 0.99 (0.99–0.99) NA 0.99 (0.99–0.99) 0.99 (0.99–0.99)
NA implies that characteristic was not included in the model since it was either an inclusion criterion (including p<0.2) or a part of the treatment measure
doi:10.1371/journal.pone.0166012.t004
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treatment with metformin and statins (IQR ranges less than 8%). Not more than 10% of the
observeddifferences, however, could be attributed to practice level, indicating that a significant
part of the differencesmay be due to patient-level differences or random variance. Of these dif-
ferences attributed to practice level, between 6% and 25% could be explained by the patient and
practice level characteristics included in our study. Patient characteristics explained almost
10% of the differences in lipid-lowering treatment compared to less than 10% for the other
treatments. Practice characteristics explainedmore than 15% of the differences in glucose-low-
ering treatment compared to less than 10% for the other treatments.
Several studies have describeddifferences in treatment rates between general practices,
showing sometimes wide ranges [27–31]. One study looked at between practice differences in
treatment with glucose-loweringdrugs in Danish patients, and found a two-fold difference in
prescription rate between the 10 and 90 percentile [28] compared to a 1.4-fold difference in
this study when calculated for these percentiles (data not shown). Another study looked at the
differences in treatment with lipid-lowering and blood pressure-lowering drugs in the UK
patients with diabetes and hypertension [27]. This study found the IQRs for treatment with
lipid-lowering drugs of 11 and for blood pressure-lowering drugs of 8, which are slightly
smaller in comparison to the IQRs of around 13 and almost 9 observed in our study. It thus
appears that the practice variation we observed among Dutch general practices is lower for glu-
cose-lowering drugs and similar for blood pressure-lowering drugs to that observedpreviously
in other countries. The small between practice differences for treatment with metformin and
statins may in part be due to restrictions on the reimbursement of some of the novel drugs,
such as DPP-4 inhibitors, GLP-1 agonists and ezetimibe.
A recent review looking at patient characteristics associated with diabetes performance indi-
cators did not find any consistent impact of demographics, complications, comorbidity, geog-
raphy or care-seeking behavior [2]. They however included only studies addressing monitoring
of risk factors, for which there may be few justified reasons not to conduct such monitoring.
For prescribing treatment, we found that patient characteristics altogether explained at least
10% of the between practices differences for treatment with lipid-lowering drugs, but less than
10% for the treatment with blood pressure-lowering drugs and glucose-loweringdrugs. For dif-
ferences in treatment with lipid-lowering drugs but also with metformin, the patients’ age was
relevant, implying that age of a patient influences the practitioners’ decisions to prescribe [32].
Since age-based prescribing in this case may be considered justified [33–35], this supports an
age-stratified assessment of these treatment rates. For treatment with lipid-lowering drugs, the
concomitant use of 3 or more glucose-regulatingdrugs explained 3% of the between practice
variance. This suggests that there is a higher probability of receiving lipid-lowering drugs in
patients with more severe diabetes. Since poormetabolic control is seen as an additional risk
factor, starting statins is usually justified in such patients [24]. For metformin the concomitant
use of 5 or more chronic drugs explained almost 7% of the variance. There seemed to be a shift
frommetformin to alternative treatment, including insulin, in patients with polypharmacy.
This could be due to more complications and intolerability issues in these patients. On the
other hand, the comorbidities and diabetes complications included in this study could not
explain the between practice differences. These findings imply that the role of comedication
and comorbidity in explaining between practice variance should be further investigated. Espe-
cially, more information is needed about other factors, such as disease severity, drug intoler-
ance and medication adherence.
Practice characteristics explained at least 15% of the between practices differences for treat-
ment with glucose-lowering drugs, and less than 10% for treatment with lipid-lowering and
blood pressure-lowering drugs. Between practice differences in health care quality of patients
with diabetes and the role of patient and practice characteristics in these differences were
Variance between Practices in Treatment of Patients with Diabetes
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examined previously [36–38]. These studies, however, focusedmainly on differences in moni-
toring of risk factors or differences in risk factor outcomes between practices. Similar to the
findings of our study, they showed that the relatively small proportion (1–12%) of differences
in quality of care can be attributed to differences between practitioners or practices [2, 36–38].
The number of T2DM patients per practice was the most relevant practice characteristic in our
study, especially for receiving any treatment (yes/no). It explained between 5% and 13% of the
treatment variance for glucose-loweringdrugs, lipid-lowering drugs, blood pressure-lowering
drugs, and RAAS-blockers.We observed a lower probability of being treated in practices with a
higher number of T2DM patients. One explanation could be that these practices are more
active in screening for diabetes, and therefore have more patients not yet in need of treatment
[39, 40]. An alternative explanation is that the practice organization in large practices may be
insufficient to provide optimal care. Although there is some evidence that practice size may
negatively influence quality of care, this finding is not consistent [41]. Of the other practice
characteristics, the presence of a physician’s assistant explained some additional variance in
treatment with statins where it seemed that statins as a first-choice drug are more prescribed in
practices with an assistant. This is in line with a finding in the UK, where prescribing of lipid
lowering drugs was more guideline concordant in patients assessed by a project nurse [42]. Sur-
prisingly, we observed a lower probability of being treated with glucose-lowering drugs in prac-
tices employing physician’s assistant. One explanation could be that the physicians’ assistants
are more consistent with guidelines resulting in a higher number of newly diagnosed patients
with T2DM per practice that may receive lifestyle advice first [40]. Overall, it appears that such
general practice characteristics can only in part explain differences in treatment rates.
The primary care system organization in the Netherlands is comparable with otherWest-
European countries [43]. The population of GIANTT cohort consists mainly of individuals of
West-European origin and is comparable with the populations of type 2 diabetes patients from
other regions of the Netherlands [3]. Around 12% of patients that were managed by a specialist
for their diabetes were excluded from the analysis, since the primary aim of the study was to
describe the differences in treatment quality of patients with diabetes between general prac-
tices. The study was based on data from the large general practice database containing a wide
range of patient characteristics, treatment and comorbidity data. More than 90% of the differ-
ences in treatment between practices, however, cannot be explained at practice level. Part of
this might be caused by the variance in other patient and practice level characteristics that we
were not able to include in our study, e.g. intolerance or unwillingness of patients for taking
specific or additional drug treatment, severity of disease, visit frequency or practice location
[44]. Because of the cross-sectional design, we could not include the level of HbA1c, choles-
terol, or blood pressure in the models. Instead we restricted all models to patients with an indi-
cation for treatment (e.g. diagnosis of hypertension or dyslipidemia). The comorbidity data in
medical records are known to be incomplete [45], which would result in underestimating their
influence on between practice variance. However, the comorbidity data in our study were
enriched by manually coding text descriptions, resulting in higher comorbidity rates compared
with that observed in a previous general practice study conducted in The Netherlands [46].
Moreover, practices with poor registration levels were excluded from our analysis. Finally, no
data were available on practitioner level characteristics, such the physician’s knowledge or atti-
tudes. Given the observedvariance at practice level, there is a need to explore other, unmea-
sured practice or practitioner characteristics [44, 47].
Measuring the quality of treatment at practice level is part of various quality improvement
initiatives [48–50]. In several countries external parties, such as insurance companies or profes-
sional organizations, use quality assessment to reward health care providers whomeet prede-
fined standards of quality. For fair assessment it is important to know whether the observed
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differences in quality of treatment between healthcare providers may be attributed to practice
level, and to what extent they can be explained by differences in the underlying patient popula-
tion. In such cases, either case-mix adjustment or stratification can be recommended [2]. The
findings of our study imply that the between practice differences in tested treatment measures
are only to a small degree affected by differences in the underlying patient population. Our
study only supports to include age as a relevant patient characteristic to reduce justifiable dif-
ferences in treatment rates, especially with lipid-lowering drugs. Other patient characteristics
either do not explain the between practice difference in treatment or do not justify these differ-
ences. Of practice characteristics, we found that the number of T2DM patients per practice and
presence of a physician’s assistant may explain between practice differences in treatment rates.
This and also other modifiable practice characteristics should be identified and explored in
future studies.
Supporting Information
S1 Appendix. Proportion of variance in treatment attributed to practice level with percent-
age reduction compared to empty model (%).
(PDF)
S2 Appendix. Description of the codelists and information required to run the algorithms.
(PDF)
Acknowledgments
The study was funded by the Department of Clinical Pharmacy and Pharmacology, University
Medical Center Groningen, the Netherlands. The funders had no role in study design, data col-












Validation: YYC GS PD.
Visualization: YYC GS PD.
Writing – original draft:YYC GS PD.
Writing – review& editing: YYC GS PD.
Variance between Practices in Treatment of Patients with Diabetes
PLOS ONE | DOI:10.1371/journal.pone.0166012 November 2, 2016 10 / 13
References
1. Van den Berg MJ, Kringos DS, Marks LK, Klazinga NS. The Dutch health care performance report:
seven years of health care performance assessment in the Netherlands. Health Research Policy and
Systems 2014; 12:1. doi: 10.1186/1478-4505-12-1 PMID: 24405849
2. Calsbeek H, Markhorst JG, Voerman GE, Braspenning JC. Case-mix adjustment for diabetes indica-
tors: a systematic review. American Journal of Managed Care 2016; 22(2):e45–e52. PMID: 26881319
3. Van Hateren KJJ, Drion I, Kleefstra N, Groenier KH, Houweling ST, van der Meer K, et al. A prospec-
tive observational study of quality of diabetes care in a shared care setting: trends and age differences
(ZODIAC-19). BMJ Open 2012; 2(4):e001387. doi: 10.1136/bmjopen-2012-001387 PMID: 22936821
4. Booth GL, Kapral MK, Fung K, Tu JV. Relation between age and cardiovascular disease in men and
women with diabetes compared with non-diabetic people: a population-based retrospective cohort
study. Lancet 2006; 368(9529):29–36. doi: 10.1016/S0140-6736(06)68967-8 PMID: 16815377
5. Manteuffel M, Williams S, Chen W, Verbrugge RR, Pittman DG, Steinkellner A. Influence of patient sex
and gender on medication use, adherence, and prescribing alignment with guidelines. Journal of Wom-
ens Health (Larchmt) 2014; 23:112–119. doi: 10.1089/jwh.2012.3972 PMID: 24206025
6. Kra¨mer HU, Raum E, Ruter G, Scho¨ttker B, Rothenbacher D, Rosemann T, et al. Gender disparities in
diabetes and coronary heart disease medication among patients with type 2 diabetes: results from the
DIANA study. Cardiovascular Diabetology 2012; 11:88. doi: 10.1186/1475-2840-11-88 PMID:
22838970
7. Satman I, Imamoglu S, Yilmaz C. A patient-based study on the adherence of physicians to guidelines
for the management of type 2 diabetes in Turkey. Diabetes Research and Clinical Practice 2012; 98
(1):75–82. doi: 10.1016/j.diabres.2012.05.003 PMID: 22652276
8. Woodard LD, Urech T, Landrum CR, Wang D, Petersen LA. Impact of comorbidity type on measures
of quality for diabetes care. Medical Care 2011; 49(6):605–610. doi: 10.1097/MLR.0b013e31820f0ed0
PMID: 21422952
9. Parnes BL, Main DS, Dickinson LM, Niebauer L, Holcomb S, Westfall JM, et al. Clinical decisions
regarding HbA1c results in primary care: a report from CaReNet and HPRN. Diabetes Care 2004;
27:13–16. PMID: 14693959
10. AB E, Denig P, van Vliet T, Dekker JH. Reasons of general practitioners for not prescribing lipid-lower-
ing medication to patients with diabetes: a qualitative study. BMC Fam Pract 2009; 10:24. doi: 10.
1186/1471-2296-10-24 PMID: 19383116
11. Brown AF, Mangione CM, Saliba D, Sarkisian CA. California Healthcare Foundation/American Geriat-
rics Society Panel on Improving Care for Elders with Diabetes. Guidelines for improving the care of the
older person with diabetes mellitus. Journal of the American Geriatrics Society 2003; 51(5) suppl:
S265–S280.
12. van Hateren KJ, Landman GW, Kleefstra N, Drion I, Groenier KH, Houweling ST, et al. Glycemic con-
trol and the risk of mortality in elderly type 2 diabetic patients (ZODIAC-20). International Journal of
Clinical Practice 2011; 65:415–419. doi: 10.1111/j.1742-1241.2010.02596.x PMID: 21401830
13. Chen S, Tseng CH. Dyslipidemia, Kidney Disease, and Cardiovascular Disease in Diabetic Patients.
The Review of Diabetic Studies: RDS 2013; 10(2–3):88–100. doi: 10.1900/RDS.2013.10.88 PMID:
24380085
14. Piette JD, Kerr EA. The impact of comorbid chronic conditions on diabetes care. Diabetes Care 2006;
29:725–31. doi: 10.2337/diacare.29.03.06.dc05-2078 PMID: 16505540
15. Pentakota SR, Rajan M, Fincke BG, Tseng CL, Miller DR, Christiansen CL, et al. Does diabetes care
differ by type of chronic comorbidity?: An evaluation of the Piette and Kerr framework. Diabetes Care
2012; 35(6):1285–1292. doi: 10.2337/dc11-1569 PMID: 22432109
16. Mathew EM, Rajiah K. Assessment of medication adherence in type-2 diabetes patients on poly phar-
macy and the effect of patient counseling given to them in a multispecialty hospital. Journal of Basic
and Clinical Pharmacy 2013; 5(1):15–18. doi: 10.4103/0976-0105.128251 PMID: 24808683
17. Greving JP, Denig P, van der Veen WJ, Beltman FW, Sturkenboom MC, Haaijer-Ruskamp FM. Deter-
minants for the adoption of angiotensin II receptor blockers by general practitioners. Social Science &
Medicine 2006; 63(11):2890–2898.
18. Peyrot M, Barnett AH, Meneghini LF, Schumm-Draeger PM. Insulin adherence behaviours and barri-
ers in the multinational Global Attitudes of Patients and Physicians in Insulin Therapy study. Diabetic
Medicine 2012; 29(5):682–689. doi: 10.1111/j.1464-5491.2012.03605.x PMID: 22313123
19. Tahrani AA, McCarthy M, Godson J, Taylor S, Slater H, Capps N, et al. Impact of practice size on deliv-
ery of diabetes care before and after the Quality and Outcomes Framework implementation. British
Journal of General Practice 2008; 58(553):576–579. doi: 10.3399/bjgp08X319729 PMID: 18682020
Variance between Practices in Treatment of Patients with Diabetes
PLOS ONE | DOI:10.1371/journal.pone.0166012 November 2, 2016 11 / 13
20. McGinn J, Davis C. Geographic variation, physician characteristics, and diabetes care disparities in a
metropolitan area, 2003–2004. Diabetes Research and Clinical Practice 2006; 72(2):162–169. doi: 10.
1016/j.diabres.2005.10.023 PMID: 16426696
21. Campmans-Kuijpers MJ, Lemmens LC, Baan CA, Gorter KJ, Groothuis J, van Vuure KH, et al. Defin-
ing and improving quality management in Dutch diabetes care groups and outpatient clinics: design of
the study. BMC Health Services Research 2013; 13:129. doi: 10.1186/1472-6963-13-129 PMID:
23561032
22. Voorham J, Denig P, Groningen Initiative to Analyse Type 2 Diabetes Treatment (GIANTT) group.
Computerized Extraction of Information on the Quality of Diabetes Care from Free Text in Electronic
Patient Records of General Practitioners. Journal of the American Medical Informatics Association:
JAMIA. 2007; 14(3):349–354. doi: 10.1197/jamia.M2128 PMID: 17329733
23. Instituut voor Verantwoord Medicijngebruik [Dutch Institute for Rational Use of Medicine]. Monitor
Voorschrijfgedrag Huisartsen [Monitor Prescribing Behavior Practice]. Utrecht: IVM. http://www.
medicijngebruik.nl/content/products/2044/attachments/rap_monitor_voorschrijfgedrag_huisartsen_
2015_20151216_s.pdf (Accessed 8 Jun 2016).
24. Nederlands Huisartsen Genootschap (NHG) [The Dutch College of General Practitioners]. Cardiovas-
culair risicomanagement (Tweede herziening) [Dutch Guideline Cardiovascular Risk Management
(Second revision)]. Huisarts Wet 2012; 55(1):14–28.
25. Lovaglio PG, Monzani E. Validation aspects of the health of the nation outcome scales. International
Journal of Mental Health Systems 2011; 5:20. doi: 10.1186/1752-4458-5-20 PMID: 21896181
26. Snijders TAB, Bosker RJ. Multilevel Analysis: An Introduction to Basic and Advanced Multilevel Model-
ing. SAGE; 2011.
27. Gulliford MC, Charlton J, Latinovic R. Trends in antihypertensive and lipid-lowering therapy in subjects
with type II diabetes: clinical effectiveness or clinical discretion?. Journal of Human Hypertension
2005; 19(2):111–7. doi: 10.1038/sj.jhh.1001787 PMID: 15361893
28. Hansen DG, Dybdahl T, Jarbøl D, Vach W. Clinical interest: a study of the influence on general practi-
tioners’ prescribing. Pharmacoepidemiology and Drug Safety 2007; 16(4):458–63. doi: 10.1002/pds.
1364 PMID: 17286321
29. Hira RS, Kennedy K, Nambi V, Jneid H, Alam M, Basra SS, et al. Frequency and Practice-Level Varia-
tion in Inappropriate Aspirin Use for the Primary Prevention of Cardiovascular Disease: Insights From
the National Cardiovascular Disease Registry’s Practice Innovation and Clinical Excellence Registry.
Journal of the American College of Cardiology 2015; 65(2):111–21. doi: 10.1016/j.jacc.2014.10.035
PMID: 25593051
30. National Health Service (NHS). Introducing the Atlas of Variation in Healthcare for People with Diabe-
tes. NHS Right Care. http://www.rightcare.nhs.uk/index.php/atlas/diabetes (Accessed 3 May 2016).
31. Simmons RK, Carlsen AH, Griffin SJ, Charles M, Christiansen JS, Borch-Johnsen K, et al. Variation in
prescribing of lipid-lowering medication in primary care is associated with incidence of cardiovascular
disease and all-cause mortality in people with screen-detected diabetes: findings from the ADDITION-
Denmark trial. Diabetic Medicine 2014; 31(12):1577–85. doi: 10.1111/dme.12574 PMID: 25185778
32. Gnavi R, Migliardi A, Demaria M, Petrelli A, Caprioglio A, Costa G. Statins prescribing for the second-
ary prevention of ischaemic heart disease in Torino, Italy. A case of ageism and social inequalities.
European Journal of Public Health 2007; 17(5):492–6. doi: 10.1093/eurpub/ckm005 PMID: 17303583
33. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering
with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;
360:7–22. doi: 10.1016/S0140-6736(02)09327-3 PMID: 12114036
34. Inzucchi SE, Lipska KJ, Mayo H, Bailey CJ, McGuire DK. Metformin in patients with type 2 diabetes
and kidney disease: a systematic review. JAMA 2014; 312(24):2668–75. doi: 10.1001/jama.2014.
15298 PMID: 25536258
35. Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM, Cobbe SM, et al. Pravastatin in elderly
individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002;
360:1623–30. PMID: 12457784
36. Dijkstra RF, Braspenning JCC, Huijsmans Z, Peters S, van Ballegooie E, ten Have P, et al. Patients
and nurses determine variation in adherence to guidelines at Dutch hospitals more than internists or
settings. Diabetic Medicine 2004; 21:586–591. doi: 10.1111/j.1464-5491.2004.01195.x PMID:
15154944
37. Krein SL, Hofer TP, Kerr EA, Hayward RA. Whom should we profile? Examining diabetes care practice
variation among primary care providers, provider groups, and health care facilities. Health Services
Research 2002; 37(5):1159–1180. doi: 10.1111/1475-6773.01102 PMID: 12479491
Variance between Practices in Treatment of Patients with Diabetes
PLOS ONE | DOI:10.1371/journal.pone.0166012 November 2, 2016 12 / 13
38. O’Connor PJ, Rush WA, Davidson G, Louis TA, Solberg LI, Crain L, et al. Variation in Quality of Diabe-
tes Care at the Levels of Patient, Physician, and Clinic. Prev Chronic Dis 2008; 5(1):A15. PMID:
18082004
39. Van den Bruel A. The triumph of medicine: how overdiagnosis is turning healthy people into patients.
Family Practice 2015; 32(2):127–128. doi: 10.1093/fampra/cmv008 PMID: 25805809
40. Janssen PG, Gorter KJ, Stolk RP, Rutten GE. Do characteristics of practices and general practitioners
influence the yield of diabetes screening in primary care? The ADDITION Netherlands study. Scandi-
navian Journal of Primary Health Care 2008; 26(3):160–165. doi: 10.1080/08037050802117924
PMID: 18609249
41. Ng CWL, Ng KP. Does practice size matter? Review of effects on quality of care in primary care. British
Journal of General Practice 2013; 63(614):e604–e610. doi: 10.3399/bjgp13X671588 PMID: 23998840
42. Mohammed MA, El Sayed C, Marshall T. Patient and other factors influencing the prescribing of car-
diovascular prevention therapy in the general practice setting with and without nurse assessment.
Medical Decision Making 2012; 32(3):498–506. doi: 10.1177/0272989X12437246 PMID: 22357626
43. van Loenen T, van den Berg MJ, Heinemann S, Baker R, Faber MJ, Westert GP. Trends towards
stronger primary care in three western European countries; 2006–2012. BMC Family Practice. 2016;
17(1):59. doi: 10.1186/s12875-016-0458-3 PMID: 27233498
44. Hong CS, Atlas SJ, Chang Y, Subramanian SV, Ashburner JM, Barry MJ, et al. Relationship between
patient panel characteristics and primary care physician clinical performance rankings. JAMA 2010;
304(10):1107–1113. doi: 10.1001/jama.2010.1287 PMID: 20823437
45. Botsis T, Bassøe C-F, Hartvigsen G. Sixteen years of ICPC use in Norwegian primary care: looking
through the facts. BMC Medical Informatics and Decision Making 2010; 10:11. doi: 10.1186/1472-
6947-10-11 PMID: 20181271
46. Struijs JN, Baan CA, Schellevis FG, Westert GP, van den Bos GA. Comorbidity in patients with diabe-
tes mellitus: impact on medical health care utilization. BMC Health Services Research 2006; 6:84. doi:
10.1186/1472-6963-6-84 PMID: 16820048
47. Kralewski J, Dowd B, Knutson D, Tong J, Savage M. The relationships of physician practice character-
istics to quality of care and costs. Health Services Research 2015; 50(3):710–29. doi: 10.1111/1475-
6773.12242 PMID: 25287759
48. Health & Social Care Information Centre. Quality and Outcomes Framework (QOF)—2014–15. http://
www.hscic.gov.uk/catalogue/pub18887 (Accessed 8 Jun 2016).
49. National Committee of Quality Assurance. HEDIS Quality Rating System Measure Technical Specifi-
cations 2015. http://www.ncqa.org/hedis-quality-measurement/hedis-measures/hedis-2015
(Accessed 8 Jun 2016).
50. The Dutch College of General Practitioners [Nederlands Huisartsen Genootschap (NHG)]. Quality indi-
cators for primary care patients with type 2 diabetes [Indicatoren kwaliteit huisartsenzorg bij patie¨nten
met DM type 2], Versie 1.7, 30 mei 2016 https://www.nhg.org/sites/default/files/content/nhg_org/
uploads/ha-indicatoren_dm2-v1.7-30mei16-specs.pdf (Accessed 5 Oct 2016).
Variance between Practices in Treatment of Patients with Diabetes
PLOS ONE | DOI:10.1371/journal.pone.0166012 November 2, 2016 13 / 13
